Medicaments for the treatment of chronic obstructive pulmonary disease

• US 20050222144A1
• Filed: 05/18/2005
• Published: 10/06/2005
• Est. Priority Date: 11/15/2002
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Original Assignee: Boehringer Ingelheim Pharma GmbH & Company Kg (C.H. Boehringer Sohn AG & Co. KG)
• Inventors: Lustenberger, Philipp, Konetzki, Ingo, Hoenke, Christoph, Rudolf, Klaus, Bouyssou, Thierry, Heine, Claudia, Pestel, Sabine, Buettner, Frank, Schnapp, Andreas, Schromm, Kurt, Schollenberger, Hermann
• Granted Patent: US 8,044,046 B2
• Time in Patent Office: Days
• US Class Current: 514/230.500
• CPC Class Codes: A61K 31/535 having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• CPC Class Codes: A61K 31/538 ortho- or peri-condensed with carbocyclic ring systems
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: C07D 265/36 condensed with one six-membered ring

Abstract

A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2;

• R¹ is hydrogen, C₁-C₄-alkyl, halogen, OH, or —O—C₁-C₄-alkyl;
• R² is hydrogen, C₁-C₄-alkyl, halogen, OH, or —O—C₁-C₄-alkyl;
• R³ is hydrogen, C₁-C₄-alkyl, OH, halogen, —O—C₁-C₄-alkyl, —O—C₁-C₄-alkylene-COOH, or —O—C₁-C₄-alkylene-CO—O—C₁-C₄-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).

Claims

1. (canceled)

27. The method according to claim 1, wherein:

R¹ is hydrogen, halogen or C₁-C₄-alkyl;

R² is hydrogen, halogen, or C₁-C₄-alkyl; and

R³ is hydrogen, C₁-C₄-alkyl, OH, halogen, —

O—

C₁-C₄-alkyl, —

O—

C₁-C₄-alkylene-COOH, or —

O—

C₁-C₄-alkylene-CO—

O—

C₁-C₄-alkyl.

28. The method according to claim 1, wherein:

R¹ is hydrogen, fluorine, chlorine, or methyl;

R² is hydrogen, fluorine, chlorine, or methyl; and

R³ is hydrogen, C₁-C₄-alkyl, OH, fluorine, chlorine, bromine, —

O—

C₁-C₄-alkyl, —

O—

C₁-C₄-alkylene-COOH, or —

O—

C₁-C₄-alkylene-CO—

O—

C₁-C₄-alkyl.

29. The method according to claim 1, wherein:

R¹ is hydrogen, methyl, or ethyl;

R² is hydrogen, methyl, or ethyl; and

R³ is hydrogen, methyl, ethyl, OH, methoxy, ethoxy, —

O—

CH₂—

COOH, —

O—

CH₂—

CO—

O-methyl, or —

O—

CH₂—

COOethyl.

30. The method according to claim 1, wherein:

R¹ is hydrogen or methyl;

R² is hydrogen or methyl; and

R³ is hydrogen, methyl, OH, methoxy, —

O—

CH₂—

COOH, or —

O—

CH₂—

COOethyl.

2. (canceled)

3. (canceled)

4. (canceled)

5. (canceled)

6. (canceled)

7. (canceled)

8. (canceled)

9. (canceled)

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. A method for the treatment of COPD comprising administration of a therpeutically effective amount of a compound of formula 1

wherein:

n is 1 or 2;

R¹ is hydrogen, C₁-C₄-alkyl, halogen, OH, or —

O—

C₁-C₄-alkyl;

R² is hydrogen, C₁-C₄-alkyl, halogen, OH, or —

O—

C₁-C₄-alkyl;

R³ is hydrogen, C₁-C₄-alkyl, OH, halogen, —

O—

C₁-C₄-alkyl, —

O—

C₁-C₄-alkylene-COOH, or —

O—

C₁-C₄-alkylene-CO—

O—

C₁-C₄-alkyl, or

an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and

a pharmaceutically acceptable excipient or carrier.